AlphAIAlphAI — Financial news for AI agents
investing.comOCT 12 min read$KYMR

B.Riley reiterates Kymera Therapeutics stock rating on new trial data

B.Riley reiterated a Buy rating and $155 price target for Kymera Therapeutics (KYMR) after new trial data. The stock is up 104% year-over-year. Analysts note potential for re-rating if BROADEN2 trial shows positive results. Multiple analysts have raised price targets, citing the Phase 2b study as a key catalyst.

Original reporting
investing.com
Published Oct 1, 2026, 9:56 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 1, 2026, 10:13 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefTechnology
Primary signal
$KYMR
Bullish
high confidence
Mentioned
$KYMR
Relevance
8/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$KYMRBullishMed
01

Why it matters

The data provide a tangible catalyst ahead of the Phase 2b BROADEN2 trial, supporting higher valuation multiples.

02

Market read

Positive early trial data can trigger a short‑term rally in KYMR and may influence sentiment toward similar biotech stocks.

03

What to watch

Potential competition from Dupixent and other IL‑4/13 blockers could limit market share.

Relevance 8/10Novelty 8/10Timing: intraday today

Background

Kymera Therapeutics (NASDAQ:KYMR) is developing oral STAT6 degraders for atopic dermatitis. The company recently presented Phase 1b data at a major dermatology conference.

Company-level read

Ticker impact

$KYMRBullishHigh confidence
Context

B.Riley reiterated a Buy rating and $155 price target on Kymera Therapeutics after new Phase 1b trial data for KT-621 was presented at EADV'26.

Expected impact

upward pressure as the market prices in the encouraging trial results

Evidence & confidence

Phase 1b data showing IL‑31 reduction and no ocular events is a material clinical milestone for a biotech, often prompting a short‑term rally.

Market effects

Sector

Strengthens the broader atopic dermatitis and STAT6 therapeutic space, may benefit peers with similar pipelines.

Regional

U.S. biotech sector could see modest uplift.

Global

Limited to biotech investors; no broader macro effect.

Counterpoint

What could challenge this read

Phase 1b data are early; efficacy and safety still unproven at scale, risk of later trial setbacks.

Key entities

  • company
    Kymera Therapeutics

    Biotech firm developing STAT6 degrader KT-621.

  • analyst
    B.Riley

    Equity research analyst who reiterated a Buy rating.

Read at source← All news

Related articles

SEP 10
$KYMRMedAI 8/10

Kymera Therapeutics at citigroup summit: oral immunology push gains pace

Kymera Therapeutics (KYMR) presented its focus on oral immunology at Citigroup's Biopharma Summit, highlighting STAT6 and IRF5 programs. STAT6 aims to treat type 2 inflammation, with Phase III readout expected by year-end 2024. IRF5 targets autoimmune diseases, with human genetics and biological validation. The company seeks to become an independent commercial entity, focusing on immunology. Kymera's stock is up 2.54% to $118.36.

investing.com2 min
SEP 1
$KYMRMedAI 8/10

Kymera Therapeutics Announces Presentations on KT-621, a First-in-Class, Oral STAT6 Degrader, at the European Respiratory Society and European Academy of Dermatology & Venereology Congresses

Kymera Therapeutics (KYMR) announced presentations on KT-621, its oral STAT6 degrader, at ERS and EADV congresses. The company completed enrollment in the BROADEN2 Phase 2b trial for atopic dermatitis, with topline data expected by year-end 2026. Phase 3 trials are planned for mid-2027. The BREADTH Phase 2b asthma trial is ongoing, with data expected in late 2027.

investingnews.com2 min
AUG 12
$KYMRMed

Kymera Therapeutics (KYMR) Q2 2026 Earnings Call Transcript

Kymera Therapeutics (KYMR) reported Q2 2026 collaboration revenue of $65M, including a $45M Gilead option fee and $20M Sanofi milestone. Cash and investments were $1.5B as of June 30, 2026, runway into 2029. R&D rose to $119.5M. KT-621 AD Phase 3 initiation is mid-2027, and asthma data is late 2027.

fool.com7 min
AUG 6
$KYMRMed

Kymera Therapeutics Announces Second Quarter 2026 Financial Results and Provides a Business Update

Kymera Therapeutics (NASDAQ: KYMR) reported Q2 2026 results and updated its pipeline. Enrollment in KT-621 BROADEN2 Phase 2b atopic dermatitis finished nearly six months early, shifting topline data to year-end 2026 and Phase 3 start to mid-2027. KT-621 asthma data is due late 2027. KT-579 Phase 1 data is expected 4Q26. Cash was $1.5B as of June 30, 2026.

investingnews.com6 min